Navigation Links
ASCO Research Foundation Grant Will Support Study of Peregrine's Bavituximab in Lung Cancer
Date:6/10/2009

ab."

Dr. Gerber, assistant professor at the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern, will receive a three-year award totaling $200,000 to support his original research, A Pilot Study of the Biologic Effects of Chemotherapy Plus Bavituximab in Patients with Advanced Non-Small Cell Lung Cancer. These competitive awards are available to promising physician researchers who are full-time faculty members in a clinical setting at an academic medical center.

Bavituximab is also currently being tested in combination with chemotherapy in two Phase II trials in advanced breast cancer. Preliminary positive results from one of these trials were the subject of an oral presentation at the 2009 ASCO Annual Meeting.

About Phosphatidylserine (PS)-Targeting Immunotherapies

The rapid and disorganized growth that is the hallmark of cancer results in the exposure of the lipid phosphatidylserine (PS) on the surface of tumor blood vessels. Since these phospholipids are typically not exposed on the surface of normal tissues, they represent a unique target for anti-cancer treatments. Bavituximab is a monoclonal antibody that binds specifically to these phospholipids exposed on the surface of the cells lining tumor blood vessels. Once bound, bavituximab alerts the body's immune system to attack the tumor blood vessels, inhibiting tumor growth and proliferation. In addition, a growing body of evidence supports the active role of PS in immune signaling, with recent research showing that exposed PS can have an immunosuppressive effect and dampen the body's normal response to cancer. By binding to and blocking PS, bavituximab is believed to boost the body's ability to combat cancer via this second immunostimulatory mechanism. Further information on the role of exposed PS in the tumor environment can be found in the Anti-PS Technical Backgrounder posted at

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. LA BioMed researcher honored for excellence in education
2. VBI researchers develop new method for breast cancer biomarker discovery
3. Early stimulus funding supports research in adolescent addiction
4. HealthCore Invites Community-based Practitioners to Participate in Real-world Research Network
5. Researchers estimate risk of transmission of Huntingtons disease to offspring among male carriers
6. Advance in bowel cancer test research
7. Canary Foundation and Stanford University Commit $20 Million for World-Class Research Center for Cancer Early Detection
8. Entest BioMedical Inc. Adds Former National Cancer Institute Researcher to Scientific Advisory Board With Focus on Stem Cell Cancer Patient Therapies
9. LSUHSC researchers first to document early signs for diabetes in kids as young as 7
10. Researchers work to boost effectiveness of the flu vaccine
11. Women underrepresented in cancer research, U-M study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... NY (PRWEB) , ... September 01, 2015 , ... ... to date, more than 1,500 investor-families have received permanent green cards (I-829 petition ... projects. , The I-829 petition is the final step of the EB-5 visa ...
(Date:9/1/2015)... ... September 01, 2015 , ... USA Medical Card, a ... week to coincide with back-to-school and the start of “sick season” for many ... elementary school children are sick an average of 8 to 12 times each ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... Self-Directed Care is, how to access caregivers and what to look for and ... and pertinent information. , Founded in 2006 in Canoga Park, CA by CEO, ...
(Date:9/1/2015)... Toronto, Canada (PRWEB) , ... ... ... Technologies announce PRO Archiver for Alfresco, a next-generation customer communications archiving ... is built with market-leading technology from Crawford and helps organizations save millions ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Elizabeth Callahan, ... one of the first in the area to offer RADIESSE® filler treatment for volume ... reduce the prominence of tendons and veins in the hands, delivering smooth, natural-looking results ...
Breaking Medicine News(10 mins):Health News:CanAm Enterprises Reaches Another Milestone with More Than 1,500 I-829 Petition Approvals 2Health News:USA Medical Card Launches New FAQ Video During Back-to-School 2Health News:AdvantagePlusCaregivers.com® Launches New Website for Corporate and Franchisee Locations in 3 States 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 3Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3
... ... heart function without need for cardiac stem cells , ... (Vocus) July 16, 2009 -- Injured heart tissue normally can,t regrow, ... heart tissue after a heart attack, in patients with heart failure, or in children with ...
... coronary function are restored , THURSDAY, JULY 23 (HealthDay ... tissue renew itself after a heart attack -- until now. ... to the heart become blocked, preventing enough oxygen from getting ... But researchers at Children,s Hospital Boston report progress toward someday ...
... , , PIPERSVILLE, Pa., July 23 ... the body,s mechanism for cooling itself is overactive and can cause ... than normal. While some people may only think about sweating during ... can disrupt their daily and recreational activities, regardless of the season. ...
... , ROANOKE, Va., July 23 Job ... The Virginia Psychological Association (VPA) and Virginia Academy of Clinical ... this cost by awarding the 2009 VPA/VACP Psychologically Healthy Workplace ... submit nominations. , , ...
... , , LOS ANGELES, July 23 ... AIDS Programs and Policy is launching its most comprehensive community outreach campaign ... of those who have HIV does not know it. , ... Titled "Virus," the multi-faceted campaign is designed to raise doubt ...
... , INDIANAPOLIS, July 23 Today, Eli ... the U.S. Food and Drug Administration (FDA) has approved a ... injection] to treat osteoporosis associated with sustained, systemic glucocorticoid therapy ... therapy is the most common cause of secondary osteoporosis, leading ...
Cached Medicine News:Health News:Study in this Week's Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 2Health News:Study in this Week's Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 3Health News:Injection May Heal Damaged Heart 2Health News:Photos: Don't Let Them See You Sweat This Summer 2Health News:Photos: Don't Let Them See You Sweat This Summer 3Health News:Photos: Don't Let Them See You Sweat This Summer 4Health News:Photos: Don't Let Them See You Sweat This Summer 5Health News:Los Angeles County Launches Its Most Comprehensive Campaign Ever to Encourage HIV Testing 2Health News:Los Angeles County Launches Its Most Comprehensive Campaign Ever to Encourage HIV Testing 3Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 2Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 3Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 4Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 5Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 6
(Date:8/31/2015)...  Ascendant Solutions, Inc. (Pink Sheets: ASDS ) ... subsidiary, Dougherty,s Holdings, has acquired Springtown Drug (" ... Springtown, Texas , just north of ... pharmacy has provided retail prescriptions, healthcare products and gifts ... . The Springtown ...
(Date:8/31/2015)... Pa. , Aug. 31, 2015 The ... reversed statewide since Pennsylvania State ... life-saving drug kits, naloxone. Heroin and opioid ... Pennsylvania , killing more individuals than ... approximately 2,400 Pennsylvanians died from a drug overdose. ...
(Date:8/31/2015)... , Aug. 31, 2015 Regen BioPharma, ... development of a novel means of delivering its ... RGBP-248, to liver tumors utilizing a clinically approved ... overcomes previous hurdles with gene silencing therapeutics in ... delivered throughout the whole body.  By utilizing a ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
... June 9 Halozyme Therapeutics,Inc. (Nasdaq: ... products targeting the extracellular matrix, today,announced new ... mellitus program at,the American Diabetes Association,s 68th ... company,s proprietary recombinant human,hyaluronidase enzyme (rHuPH20) with ...
... Pivotal Study Highlighted at Recent Arizona Alzheimer,s ... Consortium Annual Conference in Phoenix -, PHOENIX and ... Health Research Institute today announced that they are,actively enrolling patients ... treatment of Alzheimer,s disease. The study will,evaluate the safety and ...
Cached Medicine Technology:Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 2Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 3Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 4Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 5Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 2Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 3
... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: